RET and neoplasm: Lenvatinib is an oral multi-kinase inhibitor (VEGFR1-3, PDGFR, FGFR1-4, RET and c-KIT) that has demonstrated synergistic activity with pembrolizumab in pre-clinical studies (32) through its anti-angiogenic effects and ability to enhance immune cell infiltration into the tumour, thus augmenting the ICI-induced immunogenic response.